| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.21 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.11 | 0.2 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.1 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.2 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.094 | 0.2 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.094 | 0.3 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.091 | 0.3 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.099 | 0.3 |